ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 1871

Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype

Louis Lu1, Stephanie Moser2, Chad M. Brummett2 and Daniel J. Clauw3, 1Anesthesiology & Perioperative Care, UC Irvine, Orange, CA, 2Anesthesiology, University of Michigan, Ann Arbor, MI, 3Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: fibromyalgia and pain

Session Information

Date: Monday, November 6, 2017

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Fibromyalgia is challenging to diagnose given its overlapping symptoms with other chronic pain conditions. The most characteristic feature of FM is widespread pain, operationalized by the 2016 FM Survey Criteria as involving at least 4 out of 5 body regions (axial region and limbs). We hypothesized that certain pain locations may be virtually pathognomonic of FM, because these pain sites occur commonly in FM patients but are very uncommon in individuals without FM.

Methods: This is a single center retrospective observational study of patients recruited prior to elective surgery to be in an institutional biorepository. Patients completed the Michigan Body Map to assess the presence or absence of pain in 35 body sites, as well as the 2011 FM Survey Criteria. FM symptom (FS) scores were calculated by adding the widespread pain index (WPI) and symptom severity (SS) scale. Based on the 2016 Modified FM Criteria, patients were diagnosed with FM if they reported pain in 4+ body regions and their FS scores were 12+. Controls were patients that did not meet the criteria. Univariate differences were assessed via t-tests and chi-square tests. Multivariate linear regression accounted for age and gender.

Results: 891 patients (5.5%) out of 16,273 patients were diagnosed with FM. Median age for FM patients was 53 vs 54 (p = 0.62) and 72% female vs 52% (p < 0.0001). Pain sites with the highest odds ratios between FM patients and controls were the left upper arm (23.9), left lower arm (23.4), right upper arm (22.6), right lower arm (21.8), left shoulder (21.6), and right shoulder (18.7). Upon multivariate analysis, statistically significant sites were the head (p = 0.006), face (p = 0.04), left upper arm (p = 0.004), left lower arm (p = 0.0001), left wrist/hand (p = 0.02), left knee (p < 0.0001), left lower leg (p = 0.002), left ankle/foot (p = 0.007), right jaw (p = 0.01), right upper arm (p = 0.006), right elbow (p < 0.0001), right lower arm (p < 0.0001), right wrist/hand (p < 0.0001), right knee (p < 0.0001), and right lower leg (p = 0.001). See Table 1 for the results of all queried body sites.

Conclusion: Pain in non-joint regions of all four limbs, in addition to the head, face and jaw, were all statistically more significantly seen in individuals with FM and unusual in non-FM patients. Though other regions of pain were also commonly seen in FM, because they were also seen in non-FM patients, they would not be helpful in differentiating a chronic pain patient with FM vs. one with a different underlying cause.

Table 1:

Site

FM Patients

Controls

Odds Ratio

Multivariate Analysis p-value

Head

41.6%

8.7%

7.5 (6.5 – 8.7)

0.006

Face

10.2%

2.5%

4.4 (3.4 – 5.6)

0.04

Neck

66.4%

13.8%

12.4 (10.7 – 14.4)

0.08

Upper Back

53.2%

7.4%

14.2 (12.2 – 16.4)

0.79

Abdomen

35.8%

8.9%

5.7 (4.9 – 6.6)

0.53

Lower Back

84.5%

30.0%

12.7 (10.5 – 15.4)

0.10

Pelvis

27.6%

7.3%

4.9 (4.1 – 5.7)

0.80

Left Jaw

20.2%

3.1%

8.0 (6.6 – 9.6)

0.09

Left Shoulder

71.4%

10.3%

21.6 (18.5 – 25.3)

0.47

Left Upper Arm

34.0%

2.1%

23.9 (20.0 – 28.7)

0.004

Left Elbow

31.0%

2.7%

16.0 (13.4 – 19.1)

0.11

Left Lower Arm

29.0%

1.7%

23.4 (19.3 – 28.4)

0.0001

Left Wrist/Hand

59.6%

9.6%

13.9 (12.0 – 16.0)

0.02

Left Buttocks

20.1%

3.1%

8.0 (6.6 – 9.6)

0.58

Left Chest/Breast

16.5%

2.5%

7.6 (6.2 – 9.4)

0.17

Left Hip

66.4%

11.1%

15.8 (13.6 – 18.4)

0.64

Left Groin

15.3%

3.9%

4.5 (3.6 – 5.5)

0.29

Left Upper Leg

40.2%

5.2%

12.2 (10.4 – 14.2)

0.15

Left Knee

59.6%

16.6%

7.4 (6.4 – 8.6)

0.0000

Left Lower Leg

46.7%

5.8%

14.1 (12.2 – 16.4)

0.002

Left Ankle/Foot

57.6%

12.1%

9.8 (8.5 – 11.4)

0.007

Right Jaw

21.8%

3.1%

8.8 (7.3 – 10.6)

0.01

Right Shoulder

70.8%

11.5%

18.7 (16.0 – 21.8)

0.18

Right Upper Arm

33.6%

2.2%

22.6 (18.9 – 27.1)

0.006

Right Elbow

29.9%

3.0%

13.6 (11.4 – 16.2)

0.0000

Right Lower Arm

27.3%

1.7%

21.8 (17.9 – 26.5)

0.0000

Right Wrist/Hand

61.6%

10.0%

14.4 (12.5 – 16.7)

0.0000

Right Buttocks

19.5%

3.1%

7.5 (6.2 – 9.1)

0.77

Right Chest/Breast

16.2%

2.5%

7.5 (6.1 – 9.3)

0.84

Right Hip

64.9%

11.2%

14.6 (12.6 – 17.0)

0.17

Right Groin

16.3%

4.0%

4.6 (3.8 – 5.7)

0.09

Right Upper Leg

41.0%

5.2%

12.5 (10.7 – 14.6)

0.30

Right Knee

61.1%

16.7%

7.8 (6.8 – 9.0)

0.0000

Right Lower Leg

47.0%

5.6%

15.0 (12.9 – 17.5)

0.001

Right Ankle/Foot

57.8%

12.5%

9.6 (8.3 – 11.1)

0.10


Disclosure: L. Lu, None; S. Moser, None; C. M. Brummett, MDHHS (Sub K Michigan OPEN); NIH-DHHS (P90 AR070600-05 CORT) UM MICHIGAN Genomics Initiative, 2,NIDA (ntralized Pain Opiod Non-Responsiveness RO1 DA03826-05); Neuros Medical, Inc. (research funding only), 2,Peripheral Perineural Dexmedetomidine Patent, 7,NIH-DHHS-US (K23 DA038718-04) Chronic Pain through Individualized Opioid Cessation, 2,NIH-DHHS (P50 AR070600-05 CORT), 2,UM Michigan Genomics Initiative, 2,Neuros Medical, Inc. (research funding only), 2; D. J. Clauw, Abbott Pharmaceutical, 5,Aptinyx, 5,Astellas Phamaceutical, 5,Cerephex, 5,Daiichi Sankyo, 5,Pfizer Inc, 5,Pierre Fabre, 8,Samumed, 5,Theravance, 5,Tonix, 5.

To cite this abstract in AMA style:

Lu L, Moser S, Brummett CM, Clauw DJ. Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identifying-pain-sites-highly-associated-with-the-fibromyalgia-fm-phenotype/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-pain-sites-highly-associated-with-the-fibromyalgia-fm-phenotype/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology